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Parkinson’s disease (PD) presents with extensive heterogeneity in symptomatology, inviting examination of disease subtypes. One
signiﬁcant categorization is by whether patients present at onset with tremor as the dominant symptom (TD) or with nontremor
symptoms (NTD). We examined diﬀerences in quality of life between TD and NTD patients using the Parkinson’s Disease
Questionnaire-39(PDQ-39),correlatingperformancewithaspectsofmotorfunctionasindexedbytheUniﬁedParkinson’sDisease
RatingScale(UPDRS).Participantsincluded 35nondementedindividuals (19TD, 16NTD) matched onclinicalanddemographic
characteristics. NTD had signiﬁcantlyloweroverallPDQ-39 scores,particularly forthe mobilitysubscale.SeveralUPDRS subscale
scores signiﬁcantly correlated with quality of life, especially for NTD. Further, the correlations were driven by nontremor type
symptoms, even in TD patients. Determining reliable subtypes of PD may aid in prognosis and treatment optimization, thereby
enhancing quality of life in aﬄicted individuals.
1.Introduction
Parkinson’s disease (PD) is a degenerative disorder of the
central nervous system that demonstrates extensive het-
erogeneity in symptomatology, leading many investigators
to examine disease subtypes [1]. Researchers have used
predominance of speciﬁc motor symptoms, age of disease
onset, laterality of symptoms, disease severity, cognitive
performance, and several other categories to deﬁne subtypes
of PD [2].
The classiﬁcation of initial symptom has been a major
focus of recent research. Individuals displaying primarily
rigidity and gait and balance symptoms (nontremor dom-
inant; NTD) and those with mainly tremor symptoms
(tremor dominant; TD) at diagnosis present diﬀerences in
clinical and cognitive proﬁle [1–5]. In addition to exhibiting
more severe cardinal motor deﬁcits including problems
with gait and balance, NTD individuals have been shown
to have increased levels of axial motor symptoms such as
freezing, falls, and diﬃculty with speech and swallowing,
as well as nonmotor symptoms such as poorer cognitive
functioning (particularly executive deﬁcits) and increased
levelsof depression [1–3, 5]. NTD individuals have also been
shown to be more likely to experience early onset dementia
than patients with TD [1].
Clinical diﬀerences found between TD and NTD may be
related to distinct neuropathological proﬁles that contribute
to tremor or nontremor symptoms. While tremor may
implicate pathology in the cortico-striato-thalamocortical
circuits caused by progressive dopamine depletion in the
substantia nigra, the presence of both axial motor symptoms
and nonmotor symptoms may reﬂect more extensive pathol-
ogy in additional cortical and subcortical brain regions. A
recent pathological analysis demonstrated that NTD cases
had signiﬁcantly widerLewy body distributionand increased
density in the substantia nigra, frontal, and transentorhinal
regions than did TD cases. NTD patients also showed
signiﬁcantly more Alzheimer-like neuroﬁbrillary pathology
and increased plaque formation in the neocortex as well as
more frequent amyloid angiopathy [1].
Motor subtypes may be relevant to understanding spe-
ciﬁc factors that may contribute to a patient’s quality of life,
thereby providing additional targets for PD treatments and
interventions [5]. The Parkinson’s Disease Questionnaire-392 Parkinson’s Disease
(PDQ-39) is a widely used self-report measure that includes
subscales measuring mobility, activities of daily living, emo-
tional well-being, stigma, social support, communication,
cognition, and bodily discomfort [6]. Factors that have been
shown to aﬀect quality of life in PD include depression,
anxiety, cognitive functioning, motor symptom severity, and
the presence of additional axial motor symptoms [4, 7, 8].
One study found that patients with the akinetic-rigid
d i s e a s et yp eo fP De n d o r s e dm o r en e g a t i v es y m p t o m so nt h e
PDQ-39 than did individuals with the TD disease type [9].
A recent report found diﬀerences in activities of daily living
and quality of life between TD and NTD individuals even
prior to their diagnosis of PD [10]. Speciﬁcally, this study
found that individuals in the NTD group had signiﬁcant
limitations in activities of daily living and a more negative
quality of life at their initial neurologist visit prior to
any dopaminergic treatment. Even at this ﬁrst visit to the
neurologist, individuals in the NTD group had signiﬁcantly
higher scores on the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) and higher Hoehn and Yahr staging than
individuals in the TD group. Questions remain as to the
speciﬁc diﬀerences in quality of life for subgroups of PD
independentofmotor symptom severityandstageof disease.
TheMotorExamination(PartIII)oftheUPDRSincludes
26 items with scores ranging from 0 (absent or normal) to
4 (more severe impairment) [11]. Responses on the UPDRS
Motor Examination load onto six motor symptom domains
including tremor, rigidity, bradykinesia, facial expression,
speech, and axial impairments [12]. The six motor domains
can also be grouped into two subscales that represent pre-
dominantly dopaminergic or nondopaminergic symptoms
based on levodopa responsiveness [12]. The dopamine-
deﬁciency (DA) subscale includes the tremor, rigidity,
bradykinesia, and facial expression subscale scores, while
the nondopamine deﬁciency (non-DA) subscale includesthe
speech and axial symptom subscale scores [12].
To the best of our knowledge, no studies to date have
directly examined the relation between the UPDRS and its
subscaleswith thesubscales ofthePDQ-39.This comparison
could elucidate the speciﬁc symptoms that most directly
contributetoa negative qualityoflifein individualswith PD,
whichisimportantfordesigningthemosteﬀectivetreatment
plans.BecauseoftheprimacyofpoorerqualityoflifeinNTD
relative to TD patients, the present study aimed to examine
diﬀerencesin qualityoflife in these subtypesusing thePDQ-
39 and additionally to examine the associations between the
subscales of the PDQ-39 and the subscales of the UPDRS
motor examination.
2.Methods
2.1. Participants. Thirty-ﬁve nondemented patients with PD
(22 men, 13 women) were recruited from the outpatient
MovementDisordersClinicoftheDepartmentofNeurology,
Boston Medical Center. The study was approved by the
Boston University Institutional Review Board, and all par-
ticipants provided informed consent. On the modiﬁed Mini-
Mental State Examination (mMMSE) [13], a cutoﬀ score of
25 was used for PD participants as this form of the MMSE
is particularly sensitive to speciﬁc cognitive deﬁcits found
in PD without dementia (scores converted from the 57-
point scale). This version of the MMSE includes additional
executive functioning components, such as forward and
backwarddigitspan, aswell asadditionalconstructionitems.
Individuals with a history of substance abuse, head injury,
or neurologic disorders besides PD were excluded.None met
criteria for Dementia with Lewy Bodies as per McKeith [14].
Medication information was obtained for all partici-
pants. Levodopa equivalent dosages (LED) were calculated
based on previous reports with LED: (regular levodopa
dose × 1) + (levodopa controlled-release dose × 0.75) +
(pramipexole dose × 67.0) + (ropinirole dose × 16.67) +
(rotigotine × 16.67) + (pergolide dose and cabergoline
dose × 67.0) + (bromocriptine dose × 10) + ([regular
levodopa dose + levodopa controlled-release dose × 0.75) ×
0.25]) if taking tolcapone or entacapone [15].
2.2. Self-Report Measures. Motor symptom severity was
quantiﬁed using the UPDRS and Hoehn and Yahr stage
[16] .I n f o r m a t i o no nt y p eo fm o t o rs y m p t o ma to n s e t
was obtained through patient report and conﬁrmed when
possible by neurologist review. Based on the response to
the UPDRS question addressing the ﬁrst PD symptom
experienced, subjects were categorized as either TD (tremor
dominant, n = 16) or NTD (nontremor dominant, n = 19).
Mood was assessed using the Beck Depression Inventory
(BDI-2) [17] and Beck Anxiety Inventory (BAI) [18]. All
patients received the PDQ-39 [6]. Higher scores on all
questionnaires indicate more severe symptoms.
2.3. Statistical Analysis. Independent samples t-tests were
used to compare demographic and clinical characteristics
of the subgroups. The Mann-Whitney U test was used to
compare TD and NTD individuals on the PDQ-39 and
its subscales. Spearman rank order correlations were used
to examine associations between subscales of the PDQ-39
and UPDRS for all the PD participants and for TD and
NTD patients separately. A P value of <.01 was considered
signiﬁcant to control for multiple comparisons except for
subgroup analyses and where otherwise noted.
3.Results
3.1. Comparison of TD and NTD Patients on PDQ-39.
Demographic and clinical characteristics of TD and NTD
patients can be found in Table 1. TD and NTD individuals
did not signiﬁcantly diﬀer on age, UPDRS total, disease
duration, side of onset, male:female ratio, BAI, BDI, LED,
or MMSE score. Groups diﬀered signiﬁcantly on years of
education, with NTD individuals having signiﬁcantly more
years of education (P<. 05). Education was accordingly
included as a covariate in subsequent group analyses but did
not alter any of the ﬁndings.
Total PDQ-39 score was signiﬁcantly higher for NTD
individuals than TD individuals (P<. 03). A comparison of
the subscales of the PDQ-39 indicated that NTD individualsParkinson’s Disease 3
Table 1: Participant characteristics.
Age Female:male Education,
years
UPDRS,
total
Duration of
Illness, years
Ha n dY
Stage† MMSE BDI BAI
NTD
(n = 19) 64.0 (8.7) 7:12 17.7 (2.5)∗ 23.2 (9.1) 8.0 (4.3) 2 (2) 27.9 (1.2) 9.0 (4.3) 9.4 (5.9)
TD
(n = 16) 68.7 (6.2) 6:10 15.8 (1.9) 27.4 (9.4) 9.8 (5.9) 1.5 (2) 27.8 (1.0) 7.5 (5.2) 6.9 (3.2)
NTD: nontremor dominant;TD: tremor dominant;UPDRS: Uniﬁed Parkinson’s Disease Rating Scale;MMSE: Mini-Mental StateExam;H and Y: Hoehn and
Yahr; BDI: Beck Depression Inventory; BAI: Beck Anxiety Inventory. All values reported as means and standard deviations unless otherwise noted. ∗P<. 05;
†median and range are reported.
Table 2: Signiﬁcant correlations between PDQ-39 and UPDRS subscales for NTD and TD subjects.
UPDRS subscales
NTD TD
PDQ-39 subscales
ADL Communication Cognition Communication
Rigidity 0.67∗ NS NS 0.74∗∗
Bradykinesia 0.67∗∗ 0.59∗∗ NS NS
Speech 0.54∗ NS NS NS
DA-dependent 0.69∗∗ 0.61∗∗ NS NS
Facial expression NS 0.66∗∗ NS NS
Axial NS NS 0.59∗ NS
∗∗P<. 01,
∗P<. 02.
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Figure 1: Mean subscale scores on the PDQ-39 for NTD and TD
participants; ∗∗P<. 01, ∗P<. 05.
had signiﬁcantly higher scores for the PDQ-39 mobility
subscalethan TDindividuals (P<. 01),asshown in Figure 1.
There were no signiﬁcant diﬀerences between groups for the
remaining subscales of the PDQ-39.
3.2. Correlations between Scores on PDQ-39 and UPDRS.
Performance on several subscales of the UPDRS was signif-
icantly correlated with scores on the PDQ-39 subscales. In
the entire PD group, scores on the Activities of Daily Living
(ADL) subscale of the PDQ-39 correlated signiﬁcantly with
those of both the Rigidity (r = .40, P<. 01) and Dopamine-
(DA-) dependent subscales of the UPDRS (r = .44, P<
.01). Scores on the Communication subscale of the PDQ-
39 correlated signiﬁcantly with those of both the Rigidity
(r = .53, P<. 01) and Facial Expression subscales of the
UPDRS (r = .47, P<. 01).
When correlations were conducted for TD and NTD
patients separately, a diﬀerent pattern of results emerged for
the two groups. For NTD individuals, scores on the ADL
subscale of the PDQ-39 correlated signiﬁcantly with those
on the Rigidity (r = .67, P<. 02), Bradykinesia (r = .67,
P<. 01), Speech (r = .54, P<. 02), and DA subscales
of the UPDRS (r = .69, P<. 01). Additionally, scores
on the Communication subscale of the PDQ-39 correlated
signiﬁcantly with those on the Bradykinesia (r = .59,
P<. 01), Facial Expression (r = .66, P<. 01), and
DA subscales of the UPDRS (r = .61, P<. 01). For
TD individuals, scores on the Cognition subscale of the
PDQ-39 correlated signiﬁcantly with those on the Axial
subscale of the UPDRS (r = .59, P<. 02), and scores
on the Communication subscale of the PDQ-39 correlated
signiﬁcantly with those on the Rigidity subscale of the
UPDRS (r = .74, P<. 01). These results are summarized
in Table 2. NTD individuals showed a greater number of
signiﬁcant correlations between subscales of the UPDRS and
subscales of the PDQ-39 than did TD individuals. Addition-
ally, scores on the subscales of the UPDRS that correlated
with scores on the PDQ-39 were primarily those corre-
sponding to nontremor symptoms in both NTD and TD
individuals.4 Parkinson’s Disease
4.Discussion
We found that individuals with PD who experienced non-
tremor symptoms such as rigidity and gait and balance
impairments at diagnosis reported a signiﬁcantly worse
quality of life than individuals who experienced tremor as
their initial symptom. This ﬁnding was particularly signiﬁ-
cant in the domain of issues relating to mobility. Although
performance on the mobility subscale alone was signiﬁcantly
diﬀerent in NTD and TD, NTD patients endorsed a worse
quality of life than TD patients on all domains except in
the domain of social support, and their overall PDQ score
indicated signiﬁcantly worse self-perceived quality of life.
These results are in line with those from Hariz and
Forsgren, who found signiﬁcant diﬀerences in PDQ-39
scores in individuals with the TD and NTD subtypes of
PD [10]. Speciﬁcally, in their study the subgroup with NTD
had signiﬁcantly worse scores than the TD subgroup for
the mobility, ADL, Communication, and Bodily Discomfort
s u b s c a l e sa sw e l la sf o rt o t a ls c o r e s[ 10]. We found signiﬁcant
diﬀerencesbetween NTD and TD for the total PDQ-39 score
as well as for the mobility subscale score. Hariz and Forsgren
reported signiﬁcant diﬀerences between the NTD and TD
subgroups for total UPDRS scores and Hoehn and Yahr
staging, with the NTD group exhibiting more severe deﬁcits
than the TD subgroup [10]. The present study extended
these ﬁndings by showing that group diﬀerences in PDQ-
39 scores were independent of motor symptom severity or
stage of disease, as no signiﬁcant diﬀerences were found
between NTD and TD individuals for scores on the UPDRS
examination or Hoehn and Yahr staging in our sample.
Our results also demonstrated that subscales derived
from a commonly used quality of life measure, the PDQ-
39, correlated signiﬁcantly with subscales of the UPDRS. In
the entire PD group, scores on the Rigidity subscale of the
UPDRS were signiﬁcantly correlated with those on both the
ADL and Communication subscales of the PDQ-39, whereas
scores on the Tremor subscale did not correlate signiﬁcantly
with those on any PDQ-39 subscale. A separate analysis for
TD and NTD patients revealed that the correlations between
performance on the PDQ-39 and UPDRS were primarily
driven by nontremor symptoms even in TD patients. This
ﬁnding indicates that nontremor symptoms in general more
negatively impact quality of life, regardless of initial motor
symptom. The subscales of the UPDRS that pointed to
signiﬁcant relations with the quality of life subscales of
the PDQ-39 for TD individuals were for axial symptoms
and symptoms of rigidity. That is, for both TD and NTD
individuals, nontremor type symptoms appear to negatively
impact multipledomainsoftheirqualityoflife.These results
provide evidencethat tremor as a singular symptom may not
signiﬁcantly compromise quality of life, whereas symptoms
of rigidity and bradykinesia may act as more substantial
contributors to deﬁcits in self-reported quality of life.
Our ﬁndings provide insight into how the common
motor symptoms of PD negatively aﬀect speciﬁc aspects
of quality of life. For example, performance on the
Communication subscale of the PDQ-39 was signiﬁcantly
related to performance on the Facial Expression subscale
of the UPDRS, suggesting that diﬃculties with displaying
facial expressions contribute to problems with communi-
cation for patients with PD. A recent study examining
the eﬀectiveness of a randomized controlled rehabilitation
trial for PD used the PDQ-39 to evaluate improvements
in quality of life [19]. Patients demonstrated the greatest
improvementsinthecommunicationdomainofthePDQ-39
[19].This ﬁnding demonstrated thatcommunicationmaybe
signiﬁcantly related to quality of life and can be particularly
receptive to rehabilitation techniques. Accordingly, health
care providers should focus on eﬀortsto improve speech and
communication skillsin individualswith PD.Understanding
the relation between speciﬁc symptoms of PD and quality
of life may inform intervention strategies in order to most
eﬀectively improve life quality for individuals with PD.
Additionally, for the entire PD group, scores on the
ADL subscale of the PDQ-39 also correlated signiﬁcantly
with Dopamine- (DA-) dependent subscales of the UPDRS,
which includes the tremor, rigidity, bradykinesia, and facial
expression subscale scores. The non-DA-dependent subscale
includes the speech and axial symptom subscale scores of
the UPDRS. This ﬁnding provides evidence that the physical
symptoms of PD may have a larger eﬀect on self-reported
quality of life than axial symptoms. This correlation was
driven by the NTD patients, indicating that quality of life
is more aﬀected by symptoms in NTD individuals rather
than individuals with a tremor-dominant symptoms at
diagnosis.
Poorerscores onthe PDQ-39may reﬂect that individuals
with the NTD symptom proﬁle (i.e., more rigidity, gait, and
balance problems)experience more extensive disease pathol-
ogy than TD individuals [1]. While the presence of a tremor
may indicate the dopamine depletion in the substantia
nigra that negatively aﬀects cortico-striato-thalamocortical
circuits, the presence of nontremor symptoms may indicate
pathology in additional cortical and subcortical structures
of the brain, such as frontal regions and the transentorhinal
cortex [1]. Individuals with NTD may have a wider distribu-
tion and greater density of Lewy bodies in the brain than TD
individuals, which may contribute to more frequent or more
severe nontremor symptoms that ultimately have a negative
eﬀect on quality of life. These symptoms may not respond as
well to the dopaminergic treatments that have been shown
to signiﬁcantly improve the quality of life in individuals with
PD [1].
In summary, the present study provides evidence that
individuals with nontremor initial symptoms of PD endorse
a more negative quality of life than individuals who experi-
encetremorastheinitialsymptom,despitelackofdiﬀerences
in disease duration or severity. A novel ﬁnding of this study
is the demonstration of signiﬁcant correlations between
performance on speciﬁc subscales of quality of life and
speciﬁc motor symptom domains. These correlations were
driven by nontremor symptoms, even in individuals with
tremorastheinitialsymptom.Determiningreliablesubtypes
and speciﬁc motor symptom proﬁles of PD may aid in
prognosisandindividualizedtreatmentplans,aswellasassist
researchers in advancing theunderstanding oftheetiology of
PD.Parkinson’s Disease 5
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